**ORIGINAL RESEARCH**

**Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes**

Ali Saeed,1,2 Paulina Bartuzi,3 Janette Heegsma,1,4 Daphne Dekker,2 Niels Kloosterhuis,3 Alain de Bruin,3,5 Johan W. Jonker,6 Bart van de Sluis,3 and Klaas Nico Faber1,4

1Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 2Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan; 3Section of Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 4Laboratory Medicine, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 5Dutch Molecular Pathology Center, Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands; and 6Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

**BACKGROUND & AIMS:** Systemic retinol (vitamin A) homeostasis is controlled by the liver, involving close collaboration between hepatocytes and hepatic stellate cells (HSCs). Genetic variants in retinol metabolism (PNPLA3 and HSD17B13) are associated with non-alcoholic fatty liver disease (NAFLD) and disease progression. Still, little mechanistic details are known about hepatic vitamin A metabolism in NAFLD, which may affect carbohydrate and lipid metabolism, inflammation, oxidative stress and the development of fibrosis and cancer, e.g., all risk factors of NAFLD.

**METHODS:** Here, we analyzed vitamin A metabolism in 2 mouse models of NAFLD; mice fed a high-fat, high-cholesterol (HFC) diet and *Leptin<sup>−/−</sup>* mutant (*ob/ob*) mice.

**RESULTS:** Hepatic retinol and retinol binding protein 4 (RBP4) levels were significantly reduced in both mouse models of NAFLD. In contrast, hepatic retinyl palmitate levels (the vitamin A storage form) were significantly elevated in these mice. Transcriptome analysis revealed a hyperdynamic state of hepatic vitamin A metabolism, with enhanced retinol storage and metabolism (upregulated *Lrat, Dgat1, Pnpla3, Raldh*<sub>3</sub> and RAR/RXR-target genes) in fatty livers, in conjunction with induced hepatic inflammation (upregulated *Csf1, Tnfα, Nos2, Il1β, Il-6*) and fibrosis (upregulated *Col1a1, Acta2, Tgfβ3, Timp1*). Autofluorescence analyses revealed prominent vitamin A accumulation in hepatocytes rather than HSC in HFC-fed mice. Palmitic acid exposure increased *Lrat* mRNA levels in primary rat hepatocytes and promoted retinyl palmitate accumulation when co-treated with retinol, which was not detected for similarly-treated primary rat HSCs.

**CONCLUSION:** NAFLD leads to cell type-specific rearrangements in retinol metabolism leading to vitamin A accumulation in hepatocytes. This may promote disease progression and/or affect therapeutic approaches targeting nuclear receptors. ([Cell Mol Gastroenterol Hepatol 2021;11:309–325; https://doi.org/10.1016/j.cmgfh.2020.07.006](https://doi.org/10.1016/j.cmgfh.2020.07.006))

**SUMMARY**

Disturbed vitamin A metabolism in the liver of nonalcoholic fatty liver disease mice leads to cell type-specific redistribution of vitamin A, as a result of which hepatic retinol levels reduce but retinyl esters strongly accumulate in hepatocytes, rather than in hepatic stellate cells.

**Keywords:** Fatty Liver Disease; Vitamin A; Autofluorescence.
N onalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The prevalence of NAFLD is estimated at 20%–30% in the general population in Western countries. Starting with benign steatosis, patients are at risk to develop nonalcoholic steatohepatitis, and progress to cirrhosis and hepatocellular carcinoma. NAFLD prevalence is particularly high in obese individuals (80%–90%), diabetes (30%–50%), or hyperlipidemia (90%). Hepatic fat accumulation is a combined result of a high fat- and high carbohydrate-containing diet and insufficient catabolism of these energy sources, in part owing to low physical activity. A tipping point NAFLD pathology is when simple steatosis is being accompanied by hepatic inflammation and fibrosis. Inflammation leads to the activation of hepatic stellate cells (HSCs) that transdifferentiate to proliferative and migratory myofibroblasts (eg, activated HSCs) that produce excessive amounts of extracellular matrix proteins, like collagen and fibronectin, the typical feature of fibrosis.

HSCs are considered “quiescent” in the healthy liver, though they play a key role in controlling vitamin A metabolism. Vitamin A is important for many physiological processes, including reproduction, embryogenesis, glucose and lipid metabolism and vision, most of which are controlled by the retinoic acid–activated transcription factors retinoid X receptor (RXR) and retinoic acid receptor (RAR). Quiescent HSCs (qHSCs) contain the main body reserve of vitamin A, which is stored as retinyl esters in large cytoplasmic lipid droplets. Controlled conversion to retinol in qHSCs is believed to maintain stable circulating serum retinol levels around 2.0 μmol/L in humans (1.0–1.5 μmol/L in rodents). The specific (control) mechanisms involved are, however, largely unknown. Dietary vitamin A follows a complex route for storage in HSCs. In the small intestine, retinyl esters are incorporated in chylomicrons and after transport through the circulation taken up by hepatocytes. In hepatocytes, they are converted to retinol and subsequently binding to retinol binding protein 4 (RBP4) and stored in lipid droplets. Liver injury–induced activation of HSCs leads to the rapid loss of vitamin A–containing lipid droplets and, as a consequence, chronic liver diseases are associated with vitamin A deficiency, including viral hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, biliary atresia, alcoholic hepatitis, and also NAFLD. Vitamin A deficiency is defined as serum retinol levels below 0.7 mmol/L. Not only serum, but also hepatic retinol levels were found to be reduced in class III (body mass index ≥40 kg/m²) obese patients and negatively correlate with historical severity of hepatic steatosis. These analyses, however, do not take retinyl esters into account, which form the largest pool of vitamin A. It thus remains unclear whether the low serum and hepatic retinol levels truly reflect complete depletion of vitamin A stores or, alternatively, point to aberrant vitamin A metabolism in the fatty liver. Notably, individuals carrying the NAFLD risk variant of PNPLA3 (encoding adiponutrin) show low serum retinol levels, while hepatic retinyl ester levels are increased, pointing to impaired hepatic retinyl ester-to-retinol conversion. The role of disturbed vitamin A metabolism in the development of NAFLD has recently been further emphasized by the association of gene variants in HSD17B13, a retinol dehydrogenase, with hepatic steatosis. In addition, transcriptome analyses revealed a hyperdynamic state of hepatic retinol metabolism in NAFLD patients (eg, enhanced expression of genes involved in vitamin A storage, hydrolysis, and transport), though with unknown effects on the various vitamin A pools.

Thus, in this study we analyzed serum and hepatic retinol, retinyl ester, and RBP4 levels in 2 NAFLD mouse models, as well as expression of genes and proteins involved in vitamin A metabolism. Our data show that NAFLD in mice does not lead to systemic vitamin A deficiency, but rather enhances vitamin A storage in the liver while retinol levels are reduced. Importantly, bulk of the vitamin A accumulates in hepatocytes, rather than in HSCs.

Results

High Fat, High Cholesterol Diet Increases Body Weight and Liver Fat Content

In order to study the effect of NAFLD on vitamin A metabolism, we fed mice a high fat, high cholesterol (HFC)–containing diet for 12 or 20 weeks and first confirmed the development of fatty liver disease. The HFC diet induced significant body weight gain after 20 weeks (Figure 1A and B). Hepatic total and free cholesterol, as well as total triglycerides, were significantly increased after 12 weeks of HFC feeding and remained enhanced after 20 weeks (Figure 1C–E). Similarly, plasma total and free cholesterol, as well as insulin levels were significantly elevated HFC-fed mice (Figure 1F–H). Hematoxylin and eosin and Oil Red O staining confirmed excessive fat accumulation in the livers of HFC-fed mice and was associated with accumulation of CD68-positive inflammatory cells (Figure 1I).

HFC Diet Induces Markers of Hepatic Lipid Uptake and Synthesis, Inflammation, and Fibrosis in Mice

Hepatic expression of genes involved in lipid uptake (Srebl, G3b6) and synthesis (Sccoli, Fasn, Acc1, Srebplc) were strongly induced in HFC-fed mice (Figure 2A). Moreover, the HFC diet leads to an early progression to steatohepatitis, with enhanced expression of inflammatory markers, including Cd68, Tnf-α, Nos2, Cx2, Il-1β, and Il-6 (Figure 2B) as well as the progressive induction of markers of fibrosis (Coll1a1, Acta2, Tgf-β, and Timp1) (Figure 2C).

Reduced Retinol But Elevated Retinyl Palmitate in Livers of HFC-Fed Mice

Next, we determined the effect of the HFC diet on the levels of retinol in liver and plasma, as well as hepatic retinyl

Abbreviations used in this paper: HFC, high-fat, high-cholesterol; HFD, high-fat diet; HSC, hepatic stellate cell; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; qHSC, quiescent hepatic stellate cell; RAR, retinoic acid receptor; RBP4, retinol binding protein 4; RXR, retinoid X receptor.

Most current article

© 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2352-345X

https://doi.org/10.1016/j.jcmgh.2020.07.006
palmitate, the major storage form of vitamin A. On the one hand, hepatic retinol levels were comparable in 12- and 20-week chow-fed mice (24.0 ± 2.4 and 24.0 ± 2.5 μg/g liver, respectively) (Figure 3A). In contrast, hepatic retinol levels were progressively decreased in HFC-fed mice (9.1 ± 0.8 and 5.7 ± 0.8 μg/g liver after 12 and 20 weeks, respectively) (Figure 3A). On the other hand, hepatic retinyl palmitate levels progressively increased in HFC-fed mice (785 ± 34 and 1,060 ± 182 μg/g liver after 12 and 20 weeks, respectively) and were significantly higher than in Chow-fed mice (331 ± 50 and 413 ± 58 μg/g liver after 12 and 20 weeks, respectively) (Figure 3B). The disturbed hepatic retinol/retinyl palmitate balance was not accompanied by changes in plasma levels of retinol after a 12-week HFC diet (1.4 ± 0.1 and 1.6 ± 0.1 μmol/L for Chow and HFC diet, respectively), while it was increased in HFC-fed mice after 20 weeks (1.1 ± 0.1 and 2.1 ± 0.1 μmol/L for Chow and HFC diet, respectively) (Figure 3C). Hepatic RBP4 protein levels were decreased in HFC-fed mice compared with Chow-fed mice (Figure 3D), while hepatic messenger RNA (mRNA) expression of Rbp4 was comparable in all animal groups (Figure 4A). In contrast, serum RBP4 levels were elevated in HFC-fed mice, which was particularly evident after 20 weeks (Figure 3E). These results show that a drastic reduction in hepatic retinol levels in HFC-fed mice is accompanied by a significant increase in hepatic retinyl esters. Further, Pearson correlation analysis of tissue retinol levels showed a significant inverse correlation with tissue retinyl palmitate and plasma retinol levels, while tissue retinyl palmitate was not significantly correlated with plasma retinol (Figure 3F). Moreover, hepatic retinol levels in particular correlated inversely with biochemical and gene expression markers of NAFLD progression, including hepatic cholesterol and triglyceride levels, and hepatic expression of inflammatory (Tnfa, Nos2, Cld2, and Il1b) and fibrosis (Col1a1, Acta2, Tgfb, and Timp1) markers (Supplementary Table 1).

Hepatic Expression of Genes Involved in Vitamin A Storage, Transport, and Hydrolysis as Well as Retinoic Acid Targets Are Elevated in HFC-Fed Mice

Hepatic mRNA levels of Lrat, coding for the main enzyme producing retinyl esters in the liver, increased with time in HFC-fed mice (Figure 4A). No or minor changes were detected in mRNA levels for alternative retinyl-esterifying enzymes, like Dgat1 and Dgat2. Of the various retinyl ester hydrolases that mobilize retinol from hepatic retinyl ester stores, only Adpn/Pnpla3 mRNA levels were strongly induced in HFC-fed mice, while Atg1/Pnpla2 and Hsl/Lipe mRNA levels were not altered compared with Chow-fed mice. RAldh2 mRNA levels were significantly increased in livers of HFC-fed mice, while levels of other members of the retinol to retinoic acid–converting enzymes15-17 were not changed (Raldh1, Raldh3, and Raldh4) (Figure 4B). Hepatic expression of retinoic acid-responsive genes (RAR-β, Cyp26a1, Hsd17b13, Ucp2, Cpt1a, Fgf21) was enhanced in the mice fed the HFC diet (Figure 4C). Thus, an HFC diet leads to a hyperdynamic state of retinol metabolism in mice, confirming earlier observations in NAFLD patients.14

Reduced Retinol and Enhanced Retinyl Palmitate in Livers of ob/ob Mice

To validate our findings, we next analyzed hepatic vitamin A metabolism in another model of fatty liver disease (eg, the leptin-deficient ob/ob mouse). In line with the observations described previously for HFC-fed mice, hepatic retinol levels were significantly lower in ob/ob mice compared with age-matched wild-type littermates (2.8 ± 0.1 vs 16.9 ± 5.1 μg/g liver, respectively) (Figure 5A), in conjunction with strongly enhanced levels of retinyl palmitate (359 ± 28 vs 160 ± 26 μg/g liver, respectively) (Figure 5B). Moreover, plasma retinol and RBP4 levels were significantly higher in ob/ob mice as compared with their wild-type littermates (2.5 ± 0.2 vs 0.9 ± 0.2 μM retinol, respectively; Figure 5C). Finally, hepatic RBP4 protein levels were reduced in ob/ob mice independently of (unchanged) Rbp4 mRNA levels as compared with wild-type mice (Figure 5D and 6A), all features being comparable between HFC-fed wild type mice and Chow-fed ob/ob mice. Similar to HFC, plasma RBP4 levels were elevated in ob/ob mice as compared with wild-type mice (Figure 5E). Pearson correlation analysis of tissue retinol levels showed similarly a significant inverse correlation with tissue retinyl palmitate and plasma retinol levels, while tissue retinyl palmitate was not significantly correlated with plasma retinol (Figure 5F).

Hepatic Expression of Genes Involved in Vitamin A Storage, Transport, and Hydrolysis, and Retinoic Acid-Responsive Targets Are Elevated in ob/ob Mice

Similar to HFC-fed mice, hepatic expression of Lrat and Dgat1 was significantly enhanced in ob/ob mice as compared with controls, while expression of Dgat2 and Rbp4 was not different between both animal groups (Figure 6A). Pnpla3 was strongly enhanced in ob/ob mice compared with control mice, while Pnpla2 and Lipe levels were unchanged. In contrast to HFC-fed mice, RAldh2 mRNA levels were reduced in ob/ob mice, while RAldh1 and RAldh3 levels were significantly elevated (Figure 6B). Finally, hepatic expression of various retinoic acid-responsive genes was also enhanced in ob/ob mice livers as compared with controls (Figure 6C). Taken together, both NAFLD mouse models present comparable impairments in hepatic vitamin A homeostasis.
Figure 2. Expression of hepatic genes involved in lipid uptake, lipid synthesis, inflammation, and fibrosis in HFC-fed mice. Mice fed chow or HFC diet for 12 or 20 weeks were analyzed by Q-PCR for hepatic expression of genes involved in (A) hepatic lipid uptake (Srb1, Cd36) and synthesis (Scd1, Fasn, Acc1), (B) hepatic inflammation (Cd68, Tnf-α, Nos2, Ccl2, Il-1β, Il-6), and (C) liver fibrosis (Col1a1, Acta2, Tgf-β, and Timp1). Hepatic lipid uptake and synthesis, hepatic inflammation, and hepatic fibrosis were strongly increased in HFC-fed mice. *P ≤ .05, **P ≤ .01, ***P ≤ .001.
Figure 3. An HFC diet leads to impaired hepatic vitamin A metabolism in mice. Mice fed chow or HFC diet for 12 or 20 weeks were analyzed for hepatic levels of (A) retinol, (B) retinyl palmitate, and (C) plasma levels of retinol. Hepatic retinol levels were strongly reduced in HFC-fed mice, while retinyl palmitate levels were significantly increased compared with control mice. Twelve-week HFC-feeding did not alter plasma retinol levels, which were slightly elevated after 20 weeks. (D) Hepatic RBP4 protein levels were decreased in 12 week HFC-fed mice, while this decrease was no longer significant after 20 week HFC feeding. (E) Plasma RBP4 progressively increased in HFC-fed mice. (F) Correlation analysis of hepatic vitamin A (retinol, retinyl palmitate) with circulatory vitamin A (plasma retinol). *P ≤ .05, **P ≤ .01, ***P ≤ .001.
Palmitate Increases Lrat Expression and Vitamin A Accumulation in Primary Rat Hepatocytes

Dietary vitamin A is absorbed by hepatocytes through retinyl ester-carrying chylomicron remnants, after which it is redistributed to HSCs for storage (see Introduction). Thus, both hepatocytes and HSCs are possible sites for retinyl ester accumulation, and earlier work has suggested vitamin A accumulation in hepatocytes of human and rodent fatty livers. Microscopical analysis of liver tissue for vitamin A–specific autofluorescence revealed few bright (auto)

Figure 4. Hepatic expression of genes involved in vitamin A homeostasis is strongly affected in HFC-fed mice. Mice fed chow or HFC diet for 12 or 20 weeks were analyzed by Q-PCR for hepatic expression of genes and transcription factors involved in (A) vitamin A storage (Lrat, Dgat1, Dgat2) and transport (Rbp4), (B) retinyl ester hydrolysis (Atgl/Pnpla2, Pnpla3, Lipe) and retinol-to-retinoic acid conversion (Raldh1, Raldh2, Raldh3, Raldh4), and (C) retinoic acid target genes (Rar-β, Cyp26a1, Hsd17b13, Ucp2, Cpt1a, Fgf21). Hepatic expression of vitamin A storage and hydrolysis were increased in HFC-fed mice, in conjunction with enhanced expression of retinoic acid responsive genes. *P ≤ .05, **P ≤ .01, ***P ≤ .001.
fluorescent dots in the hepatic parenchyme of chow-fed mice (Figure 7A, middle top panel) reminiscent of the distribution of quiescent HSCs and the pattern observed by others in healthy rat and human livers. The autofluorescence signal strongly increased in livers of HFC-fed mice, showing a completely altered staining pattern, which

**Figure 5. Ob/ob mice show disturbed hepatic vitamin A metabolism.** Ob/ob mice and age-matched wild-type littermates were sacrificed and analyzed for (A) hepatic retinol, (B) hepatic retinyl palmitate, (C) plasma retinol, and (D) hepatic and (E) plasma RBP4 levels. Hepatic retinol levels were strongly reduced, while retinyl palmitate levels were significantly increased in ob/ob mice. Plasma retinol and RBP4 protein levels were significantly elevated in ob/ob mice. In contrast, hepatic RBP4 protein levels were reduced. Note that hepatic RBP4 mRNA levels were not changed in ob/ob mice (see Figure 6A). (F) Correlation analysis of hepatic vitamin A (retinol, retinyl palmitate) with circulatory vitamin A (plasma retinol). *P ≤ .05, **P ≤ .01, ***P ≤ .001.
levels were elevated by palmitate exposure specifically in hepatocytes. Moreover, cellular retinyl palmitate levels significantly increased only in primary rat hepatocytes exposed to palmitate together with retinol for 48 hours (Figure 7B). Conversely, 
Pnpla3 mRNA levels were elevated by palmitate exposure specifically in HSCs. Moreover, cellular retinyl palmitate levels significantly increased only in primary rat hepatocytes exposed to palmitate together with retinol for 48 hours (Figure 7C).

These results suggest that NAFLD promotes vitamin A loss in HSCs while vitamin A storage is induced in hepatocytes.

**Discussion**

In this study, we show that steatohepatitis in mice heavily affects hepatic vitamin A metabolism, leading to reduced retinol and enhanced retinyl ester levels in the liver. Notably, retinyl esters accumulate in hepatocytes rather than in HSCs, cells that store vitamin A esters in a healthy liver. Following retinol levels, hepatic RBP4 levels are also reduced, while increased in circulation. Thus, steatohepatitis does not lead to true vitamin A deficiency as suggested by earlier studies, but rather leads to hepatic retinol deficiency due to metabolic changes. Vitamin A supplementation in the form of retinyl esters may therefore be counterproductive in NAFLD, as it will likely accumulate in the already overloaded hepatocytes. Also, aberrant vitamin A metabolism may directly affect the activity of nuclear receptors, such as RAR, PPARs, LXR, and FXR, as they require RXR for most of their actions.

Chronic liver diseases, including NAFLD, are associated with low serum and hepatic retinol levels, which is generally considered to be a sign of systemic vitamin A deficiency. Moreover, serum and hepatic retinol levels are negatively correlated with liver disease progression. However, systemic retinol levels are only a very small fraction of the total pool of vitamin A, which mostly consists of retinyl esters stored in liver (>80%) and adipose tissue (10%–20%). Thus, systemic retinol levels alone are not a reliable marker for hypovitaminosis A per se.

Available information about the hepatic levels of the various retinoids (retinyl esters, retinol and retinoic acids) in NAFLD patients and animal models of NAFLD is highly controversial. Recent studies suggested that levels of all retinoids are reduced in mouse and human NAFLD livers, while earlier studies reported that NAFLD is associated with hepatic vitamin A accumulation in humans and rodents. Detailed knowledge about this is, however, crucial for patient care, as it will indicate whether vitamin A supplementation or therapy with specific vitamin A metabolites may have therapeutic value.

Our study largely confirms the reduction in hepatic retinol concentrations in fatty livers, as reported by others but reports the opposite effect for hepatic retinyl palmitate levels. Others reported that also retinyl palmitate levels in the livers of high-fat diet (HFD)–fed mice and ob/ob mice as well as human NAFLD were decreased. Several reasons may account for this discrepancy. First was HFD vs HFC diet: A high-fat (only) diet may affect vitamin A metabolism differently than the HFC diets used in this study. However, we did not detect a reduction in hepatic retinyl palmitate levels in mice fed an HFD for 12 weeks, while hepatic retinol levels were reduced in both HFD- and HFC-fed mice (Figure 3A and 8). Second was the amount of vitamin A in the diets: in our study, both the control chow and HFC diet contained equal amounts of vitamin A (eg, 20 IU/g). The earlier study used an HFD that contained significantly less vitamin A compared with the control chow (3.8 vs 15 IU/g plus additional β-carotene, respectively). Dietary intake of vitamin A, even above daily recommendations, correlates directly with hepatic levels of retinyl palmitate and retinol. Thus, for establishing an effect of a (high-fat) diet on hepatic vitamin A metabolism, it is crucial to standardize the dietary vitamin A intake for control and experimental diet. This is the case in the ob/ob mouse studies and cannot explain the opposing results between our and the earlier study. Third, retinol/retinyl ester extraction procedure: extraction of retinol and retinyl esters from serum or tissue is typically performed with either n-hexane or acetonitrile, though this is not always specified in methods sections. We compared both methods and found that acetonitrile very inefficiently extracts retinyl palmitate specifically from fatty liver tissue, while retinol extraction was similar with these solvents (Figure 9). This suggests that the extraction of retinyl esters by acetonitrile is compromised when a lot of fat is present in the (liver) tissue. Especially this latter procedural finding may explain the controversial findings on retinyl ester levels in fatty livers.

We show that hepatic fat accumulation in mice is associated with a strong reduction in hepatic retinol levels, but not in circulation. This is in line with earlier observations and indicates that the mouse NAFLD models used do show the hepatic phenotype but do not replicate the reduced circulatory retinol levels observed in NAFLD patients. NAFLD mouse models likely reflect only the initiating phase of NAFLD, and serum retinol levels are also hardly affected at that stage in patients. Alternatively, the observed difference may be species related, but this requires analyses of vitamin A metabolism in more severe mouse NAFLD models. We did observe, however, that serum RBP4 levels are elevated in NAFLD mice, which is also found in obese individuals with or without established NAFLD. In contrast, hepatic RBP4 levels are reduced...
in NAFLD mice. This implies that, even though hepatic retinol levels are low, sufficient retinol is produced to promote—and even enhance—RBP4 secretion from the liver. Efficient RBP4 secretion from the liver strongly depends on retinol availability. Vitamin A deficiency leads to pronounced hepatic accumulation of retinol-free apo-RBP4 under unchanged Rbp4 mRNA levels and is rapidly released into the circulation upon retinol or retinoic acid

![Graph A](image)

**Gene promoting hepatic vitamin A storage & transport**

![Graph B](image)

**Genes promoting retinyl ester hydrolysis and retinoic acid production**

![Graph C](image)

**Retinoic acid target genes**

**Figure 6. Hepatic expression of genes involved in vitamin A homeostasis is strongly affected in ob/ob mice.** Ob/ob mice and age-matched wild-type (WT) littermates were sacrificed and analyzed by Q-PCR for hepatic expression of genes and transcription factors involved in (A) vitamin A storage (Lrat, Dgat1, Dgat2), transport (Rbp4), (B) vitamin A hydrolysis (Atgl/Pnpla2, Pnpla3, Lipe) and retinol-to-retinoic acid conversion (Raldh1, Raldh2, Raldh3, Raldh4), and (C) retinoic acid target genes (Rar-β, Cyp26a1, Hsd17b13, Ucp2, Cpt1a, Fgf21). Hepatic expression of vitamin A storage and hydrolysis was increased in ob/ob, in conjunction with enhanced expression of retinoic acid responsive genes. *P ≤ .05, **P ≤ .01.
Figure 7. Accumulation of vitamin A in lipid-loaded hepatocytes in vivo and in vitro. (A) Oil Red O staining (left panels) and vitamin A–specific autofluorescence (middle panels) immunohistochemistry of LRAT (right panels) of liver sections of chow-fed (top panels) and HFC-fed (bottom panels) mice. Vitamin A–specific autofluorescence was strongly increased in livers of HFC-fed mice and was located predominantly in hepatocytes compared with its location in sparsely present HSCs in livers of chow-fed mice. (B) Freshly isolated and 4-hour attached primary rat hepatocytes and quiescent primary HSCs were and immediately treated with and without palmitate (PA) for 24 hours. Cells were harvested and analyzed by Q-PCR analysis for Lrat and Pnpla3 expression. The gene expression is presented in 2^ΔΔCT and normalized to 18S. (C) Freshly isolated and 4-hour attached primary rat hepatocytes were treated for 48 hours with and without PA and retinol (ROH), followed by analysis of cellular retinyl PA and ROH levels. *P ≤ .05, **P ≤ .01.
As hepatic retinol levels were low, enhanced RBP4 secretion may also result from enhanced production of retinoic acids. Indeed, mRNA levels of Raldh1, the main enzyme responsible for RA production in the liver, were significantly elevated in ob/ob mice, with similar trends observed for 12- and 20-week HFC-fed mice. A similar increase in RALDH1 (ALDH1A1) expression in human nonalcoholic steatohepatitis liver was recently reported, though retinoid acid levels were reduced, when compared with control livers. We observed a more general hepatic induction of RA-responsive genes in NAFLD mice, including RAR-β, Cyp26a1, Hsd17b13, Ucp2, Cpt1a, and Fgf21, which is in line with the earlier reported hypermetabolic state of hepatic vitamin A metabolism and degradation in NAFLD patients. It may be important now to establish whether the expression of Lrat and Dgat1, genes that encode enzymes that esterify retinol, were enhanced in NAFLD mice, with similar trends observed for retinyl palmitate. Notably, Lrat expression was induced in primary rat hepatocytes exposed to palmitate and they accumulate retinyl palmitate when co-exposed to retinol. These conditions did not regulate Lrat expression in qHSCs, but rather enhance retinyl ester hydrolysis by increasing PNPLA3 expression. These findings are in line with the shift in the main location of vitamin A to hepatocytes in fatty liver in mice (this study), rats, and humans. The redistribution of retinyl esters from HSCs to hepatocytes may also promote NALFD-associated fibrosis, as differentiation of qHSCs to myofibroblasts is characterized by the loss of vitamin A-containing lipid droplets. In NAFLD, this apparently happens in conjunction with pronounced accumulation of retinyl esters in the liver, but then primarily in hepatocytes.

The mechanism[s] underlying the differential palmitate-mediated regulation of Lrat and Pnpla3 in hepatocytes and HSCs remain[s] to be determined. Saturated fatty acids, such as palmitate, regulate various transcriptional pathways that can directly or indirectly influence (cell type–specific) hepatic vitamin A metabolism. Hepatic de novo lipogenesis is under the primary transcriptional control of HFD and saturated fatty acids, such as palmitate, affect a multitude of transcription factors, including the sterol response element-binding protein-1c (SREBP-1c), carbohydrate response element-binding protein (ChREBP), CAAT/enhancer-binding protein-α (C/EBP α or β), hepatic nuclear factor-4α (HNF-4α), peroxisome proliferator-activated receptor α and γ (PPARα and γ), chicken ovalbumin upstream promoter transcription factor (COP5-TP), forhead box 0 (FOXO), cAMP regulatory element-binding protein (CREBP), and nuclear factor κB. Indeed, PNPLA3 expression is under the direct control of SREBP-1c and ChREBP and thus palmitate-induced SREBP-1c and ChREBP may enhance hepatic PNPLA3 and thereby promote retinyl ester loss. It will be therefore interesting now to analyze the possible contribution of the various transcription factors to Lrat and Pnpla3 regulation in hepatocytes and HSCs. Additionally, palmitate may induce general cellular responses, such as cellular endoplasmic reticulum stress, protein turnover, autophagy, mitochondrial dysfunction, and cell death that may indirectly affect vitamin A metabolism.

Taken together, our study shows that fatty liver disease is associated with hepatic accumulation of retinyl esters and disturbed vitamin A metabolism. The latter condition likely modulates disease progression, as it was recently shown esters in lipid-loaded hepatocytes may therefore result from decreased hydrolysis or increased esterification. On the one hand, expression of Atg1/Pnpla2 (hydrolysis) was not changed, while both Lrat and Dgat1 (esterification) were enhanced in mouse fatty livers, indicating a shift to vitamin A storage in retinyl esters. On the other hand, PNPLA3/ADPN is also able to hydrolyze retinyl esters and its expression is strongly increased in mouse fatty liver, like in human NAFLD patients. Still, PNPLA3’s main substrates are triglycerides that also strongly accumulate in mouse fatty liver. This implies that its activity cannot compensate for the build-up of triglycerides in hepatocytes, as observed for retinyl palmitate. Notably, Lrat expression was induced in primary rat hepatocytes exposed to palmitate and they accumulate retinyl palmitate when co-exposed to retinol. These conditions did not regulate Lrat expression in qHSCs, but rather enhance retinyl ester hydrolysis by increasing PNPLA3 expression. These findings are in line with the shift in the main location of vitamin A to hepatocytes in fatty liver in mice (this study), rats, and humans. The redistribution of retinyl esters from HSCs to hepatocytes may also promote NALFD-associated fibrosis, as differentiation of qHSCs to myofibroblasts is characterized by the loss of vitamin A-containing lipid droplets. In NAFLD, this apparently happens in conjunction with pronounced accumulation of retinyl esters in the liver, but then primarily in hepatocytes.

The mechanism[s] underlying the differential palmitate-mediated regulation of Lrat and Pnpla3 in hepatocytes and HSCs remain[s] to be determined. Saturated fatty acids, such as palmitate, regulate various transcriptional pathways that can directly or indirectly influence (cell type–specific) hepatic vitamin A metabolism. Hepatic de novo lipogenesis is under the primary transcriptional control of HFD and saturated fatty acids, such as palmitate, affect a multitude of transcription factors, including the sterol response element-binding protein-1c (SREBP-1c), carbohydrate response element-binding protein (ChREBP), CAAT/enhancer-binding protein-α (C/EBP α or β), hepatic nuclear factor-4α (HNF-4α), peroxisome proliferator-activated receptor α and γ (PPARα and γ), chicken ovalbumin upstream promoter transcription factor (COP5-TP), forhead box 0 (FOXO), cAMP regulatory element-binding protein (CREBP), and nuclear factor κB. Indeed, PNPLA3 expression is under the direct control of SREBP-1c and ChREBP and thus palmitate-induced SREBP-1c and ChREBP may enhance hepatic PNPLA3 and thereby promote retinyl ester loss. It will be therefore interesting now to analyze the possible contribution of the various transcription factors to Lrat and Pnpla3 regulation in hepatocytes and HSCs. Additionally, palmitate may induce general cellular responses, such as cellular endoplasmic reticulum stress, protein turnover, autophagy, mitochondrial dysfunction, and cell death that may indirectly affect vitamin A metabolism.

Taken together, our study shows that fatty liver disease is associated with hepatic accumulation of retinyl esters and disturbed vitamin A metabolism. The latter condition likely modulates disease progression, as it was recently shown
that even moderate changes in hepatic RA production significantly enhance hepatic lipid accumulation.\textsuperscript{51} Moreover, lipid metabolism is tightly controlled by various nuclear receptors, like PPARs, FXR, LXR, and RAR, ligands of which are in advanced clinical trial stages for the treatment of NAFLD.\textsuperscript{46} All these factors require RXR as obligate partner and aberrant production of RXR-activating retinoids will affect nuclear receptor/RXR signaling. Further studies are needed to determine the impact of changed vitamin A metabolism in NAFLD on the therapeutic efficacy of these drug targets.

**Materials and Methods**

**Animals**

Animal experiments were approved by the Institutional Animal Care and Use Committee, University of Groningen, the Netherlands. Briefly, age- and sex-matched (8–10 weeks old) C57BL/6J mice were fed either regular chow or an HFC diet (containing 21% fat, with 45% calories from butterfat and 0.2% cholesterol; SAFE [Scientific Animal Food and Engineering], Villemoisson-sur-Orge, France) for a period of 12 or 20 weeks (n = 8), as reported previously.\textsuperscript{52,53} Both diets contained 20 IU of retinyl acetate/g as a source of vitamin A. Leptin\textsuperscript{ab} mutant (JAX ob/ob) mice (10–12 weeks old; Charles River Laboratories, Wilmington, MA) and appropriate controls (C57BL/6J) were also studied and received chow diet. Animals were kept in a pathogen-free environment with alternating dark-light cycles of 12 hours, and controlled temperature (20–24°C) and relative humidity (55 ± 15%) receiving food and water ad libitum. Animals were fasted 4 hours before sacrifice. Tissues were snap-frozen in liquid nitrogen or fixed in paraformaldehyde. Blood was collected by heart puncture.

**Isolation and Culture of Primary Rat Hepatocytes and HSCs**

Primary rat hepatocytes and HSCs were isolated from Wistar rats (Charles River Laboratories) and cultured as previously described.\textsuperscript{54} Briefly, primary hepatocytes were isolated after 2-step collagenase perfusion (Sigma-Aldrich, St. Louis, MO).\textsuperscript{55,56} Cell viability >80% was determined by Trypan blue (Sigma-Aldrich). Primary hepatocytes were used after 4 hours of attachment on collagen-coated plates in William’s E (Gibco by Life Technologies; Thermo Fisher Scientific, Bleiswijk, the Netherlands) medium with 10% fetal calf serum, 50–μg/mL gentamycin, and 100-U/mL penicillin/streptomycin/amphotericin B. Primary rat HSCs were isolated after pronase (Merck, Amsterdam, the Netherlands) and collagenase-P (Roche, Almere, the Netherlands) perfusion and followed by Nycodenz (Axis-ShieldPOC; Oslo, Norway) density gradient centrifugation.\textsuperscript{55} Primary hepatocytes and HSCs were exposed to bovine serum albumin–conjugated palmitic acid (0.25 or 0.5 mmol/L; Sigma-Aldrich), with or without 5–μM retinol (Sigma-Aldrich) for 24–48 hours as previously described.\textsuperscript{57}

**Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction**

Quantitative real-time reverse transcription polymerase chain reaction was performed as previously described.\textsuperscript{58} Briefly, total RNA was isolated from tissue samples using TRIzol reagent according to supplier’s instructions (Thermo Fisher Scientific). RNA quality and quantity were determined using a Nanodrop 2000c UV-vis spectrophotometer (Thermo Fisher Scientific). Complementary DNA was synthesized from 2.5 μg of RNA by using random nonamers and M-MLV reverse transcriptase (Thermo
Western Blot Analysis

Protein samples were prepared for Western blot analysis as described previously.79 Protein concentrations were quantified using the Bio-Rad protein assay (Bio-Rad, Hercules, CA) with bovine serum albumin as standard. Equal amounts of protein were separated on Mini-PROTEAN TGX precast 4%-5% gradient gels (Bio-Rad) and transferred to nitrocellulose membranes using the Trans-Blot turbo transfer system (Bio-Rad). Primary antibodies (anti-RBP4, 1:2,000; #ab109193 [Abcam, Cambridge, United Kingdom] and anti-GAPDH, 1:40,000 #CB1001 [Calbiochem; Merck-Millipore, Amsterdam-Zuidoost, the Netherlands]) and horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:2000; Agilent DAKO, Amstelveen, the Netherlands) were used for detection. Proteins were detected using the Pierce ECL Western blotting kit (Thermo Fisher Scientific). Images were captured using the chemidoc XRS system and Image Lab version 3.0 (Bio-Rad). The intensity of bands was quantified using ImageJ version 1.51 (National Institutes of Health, Bethesda, MD).

Histology and Pathological Scoring

Hematoxylin and eosin (hematoxylin and eosin) staining on liver sections (4 μm) was performed. Snap-frozen liver sections (5 μm) were stained using Oil Red O.80,81 A pathological score was calculated as previously described82 to determine the level of steatosis, as well as the grade of lobular inflammation.

Immunohistochemistry

Immunohistochemistry for CD68 (1:300; rabbit anti-mouse CD68; #137002; Biolegio, Nijmegen, the Netherlands) and LRAT (1:200 rabbit anti-mouse LRAT; #28075; Takara Immuno-Biological Laboratories, Gunma, Japan) was performed on snap-frozen liver sections as previously described.83 Antigen retrieval was performed by microwave irradiation in citrate buffer, pH 6.0, and blocking of endogenous peroxidase with 0.3% H2O2 for 30 minutes. Horseradish peroxidase-conjugated goat anti-rabbit antibodies (1:50; #170-6515; Bio-Rad) was used as secondary antibody. Slides were stained with DAB for 10 minutes and hematoxylin was used as a counter nuclear stain (2 minutes at room temperature). Finally, slides were dehydrated and mounted with Eukitt (Sigma-Aldrich). Slides were scanned using a nanozoomer 2.0 HT digital slide scanner (C9600-12; Hamamatsu Photonics, Hamamatsu, Japan) and analyzed with Aperio ImageScope (version 11.1; Leica Microsystems, Amsterdam, the Netherlands). CD68-positive cells were counted to assess the expansion of macrophages in the liver.

Lipid Analysis

Lipids were extracted from 15% (w/v) liver homogenate in phosphate-buffered saline by using the Bligh and Dyer method.84 A colorimetric assay was used to determine total cholesterol (11489232; Roche Molecular Biochemicals, Almere, the Netherlands) and free cholesterol (113609910930; DiaSys Diagnostic Systems GmbH, Holzheim, Germany). Cholesterol standards (DiaSys Diagnostic Systems GmbH) were used as a reference. Triglycerides were quantified using the Trig/GB kit (1187771; Roche Molecular Biochemicals), and Roche Precimat Glycerol standards (16658800) were used as a reference.

Serum and Hepatic Vitamin A Analysis

Serum and tissue vitamin A content was analyzed by reverse-phase high-performance liquid chromatography as previously described.85 Briefly, tissue (30–50 mg) was homogenized in phosphate-buffered saline to create a 15% (w/v) tissue homogenate. Then, tissue homogenate (66.70 μL equal to 10 mg of tissue) or serum (50 μL) were added in antioxidant mix (2.75 mL, containing 23.07-mmol/L pyrogallol, 1.32-mmol/L butylated hydroxytoluene, 5.83-mmol/L ethylenediaminetetraacetic acid, and 38.71-mmol/L ascorbic acid, dissolved in methanol:dH2O [2.67:1], pH 5.4) and vortexed thoroughly for 1 minutes.

Retinol and retinyl esters were extracted and deproteinized twice with n-hexane in the presence of retinol acetate (100 μL, concentration 4 μmol/L) as an internal standard to assess the level of recovery after the extraction procedure. Standard curves created from a range of concentrations of retinol and retinyl palmitate were used to determine absolute tissue and serum concentrations of these compounds. Additionally, 2 negative controls (only containing internal standard) and 2 positive controls (low and high concentrations of retinol plus internal standard) were included in each series of extractions. Samples were evaporated under N2 and diluted in 300-μL 100% ultrapure ethanol. Then, 50 μL was injected in high-performance liquid chromatography (HT Separations Module 2795; Waters Alliance, East Lyme, CT) for phase separation on a C18 column (Waters Symmetry C18, dimension 150 × 3.0 mm, particle size 5 μm; Waters Corporation, Milford, MA) and measurement (UV-VIS, dual wavelength, UV-4075 Jasco, Tokyo, Japan). Retinoids in samples were identified by exact retention time of known standards in ultraviolet absorption at 325 nm by high-performance liquid chromatography. Finally, retinol and retinyl palmitate concentrations were calculated and normalized to final volume or tissue weight.

Vitamin A Auto fluorescence in Liver Tissue

Autofluorescence analysis was performed on unstained cryostatic liver sections using a Zeiss LSM 780 NLO 2-
photon CLSM (Carl Zeiss, Jena, Germany) as previously described. Briefly, cryostat liver sections were illuminated with an excitation filter of 366-nm band-pass interference, and spectra were recorded in the range of 400–680 nm with spectrum acquisition from 0.2 to 3 seconds.

**Statistical Analysis**

Data is presented in group mean ± SEM and statistical analysis was performed using the GraphPad Prism 6 software package (GraphPad Software, San Diego, CA). Statistical significance was determined by Mann-Whitney test (2 groups), One-way analysis of variance or Kruskal-Wallis (more than 2 groups) followed by post hoc Dunn's test (compare all pairs of columns). Pearson correlation was performed between tissue and circulating vitamin A with various parameters of NAFLD progression.

**References**

1. Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018; 7:F1000 Faculty Rev-720.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155–161.
3. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. Metabolism 2017;68:119–132.
4. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 2013;1832:876–883.
5. Schreiber R, Taschler U, Preiss-Landl K, Wongsiriroj N, Zimmermann R, Lass A. Retinyl ester hydrolases and their roles in vitamin A homeostasis. Biochim Biophys Acta 2012;1821:113–123.
6. Blaner WS, O’Byrne SM, Wongsiriroj N, Kluwe J, D’Ambrosio DM, Jiang H, Schwabe RF, Hillman EMC, Piantedosi R, Libien J. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta 2009;1791:467–473.
7. Seno H, Mezaki Y, Fujiwara M. The stellate cell system (vitamin A-storing cell system). Anat Sci Int 2017; 92:367–455.
8. Saeed A, Hoekstra M, Hoeke MO, Heegsma J, Faber KN. The interrelationship between bile acid and vitamin A homeostasis. Biochim Biophys Acta 2017; 1862:496–512.
9. Brown E, Akré J, eds. Indicators for assessing vitamin A deficiency and their application in monitoring and evaluating intervention programmes. Geneva, Switzerland: World Health Organization, 1996.
10. Chaves GV, Pereira SE, Saboya CJ, Spitz D, Rodrigues CS, Ramalho A. Association between liver vitamin A reserves and severity of nonalcoholic fatty liver disease in the class III obese following bariatric surgery. Obes Surg 2014;24:219–224.
retinol and carotenoids with overweight in children and adolescents. Nutrition 2007;23:392–397.
24. Neuhouser ML, Rock CL, Eldridge AL, Kristal AR, Patterson RE, Cooper DA, Neumark-Sztainer D, Cheskin LJ, Thornquist MD. Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. J Nutr 2001;131:2184–2191.
25. Kane MA, Foliash AE, Napoli JL. HPLC/UJ quantitation of retinal, retinol, and retinyl esters in serum and tissues. Anal Biochem 2008;378:71–79.
26. Blaner WS, Li Y, Brun P-J, Yuen JJ, Lee S-A, Clugston RD. Vitamin A absorption, storage and mobilization. Subcell Biochem 2016;81:95–125.
27. Zhong G, Kirkwood J, Won K-J, Tjota N, Jeong H, Isoherranen N. Characterization of vitamin A metabolism in human livers with and without nonalcoholic fatty liver disease. J Pharmacol Exp Ther 2019;370:92–103.
28. Suano de Souza FI, Silverio Amancio OM, Saccardo Sami RO, Sacchi Pitta T, Fernandes AP, Affonso Fonseca FL, Hix S, Ramalho RA. Non-alcoholic fatty liver disease in overweight children and its relationship with retinol serum levels. Int J Vitam Nutr Res 2008;78:27–32.
29. Sundaesran PR, Kaup SM, Wiesenfeld PW, Chirtel SJ, Hight SC, Rader JI. Interactions in indices of vitamin A, zinc and copper status when these nutrients are fed to rats at adequate and increased levels. Br J Nutr 1996;75:915–928.
30. Johansson I, Hallmans G, Wikman A, Biessy C, Ross AC. Chronic vitamin A status and acute repletion with retinyl palmate are determinants of the distribution and catabolism of all-trans-retinolino acid in rats. J Nutr 2007;137:63–70.
31. Cifelli CJ, Ross AC. Chronic vitamin A status and acute repletion with retinyl palmate are determinants of the distribution and catabolism of all-trans-retinolino acid in rats. J Nutr 2007;137:63–70.
32. Olivares A, Daza A, Rey AI, López-Bote CJ. Dietary vitamin A concentration alters fatty acid composition in pigs. Meat Sci 2009;81:295–299.
33. Kim Y-K, Quadro L. Reverse-phase high-performance liquid chromatography (HPLC) analysis of retinol and retinyl esters in mouse serum and tissues. Methods Mol Biol 2010;652:263–275.
34. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol-binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.
35. Haider DG, Schindler K, Prager G, Bohdajian A, Luger A, Wolzt M, Ludvik B. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007;92:1168–1171.
36. Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:2287–2293.
37. Tajtálková M, Semanová Z, Ivancová G, Petrovicová J, Donicová V, Zemberová E. Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. Vnitř Lek 2007;53:960–963.
38. Ulgen F, Herder C, Kühn MC, Willenberg HS, Schott M, Scherbaum WA, Schinner S. Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem 2010;116:57–62.
39. Ronne H, Ocklind C, Wiman K, Rask L, Obrink B, Peterson PA. Ligand-dependent regulation of intracellular protein transport: effect of vitamin A on the secretion of the retinol-binding protein. J Cell Biol 1983;96:907–910.
40. Dixon JL, Goodman DS. Studies on the metabolism of retinol-binding protein by primary hepatocytes from retinol-deficient rats. J Cell Physiol 1987;130:14–20.
41. Bellovino D, Lanyau Y, Garaguso I, Amicone L, Cavallari C, Tripodi M, Gaetani S. MMH cells: An in vitro model for the study of retinol-binding protein secretion regulated by retinol. J Cell Physiol 1999;181:24–32.
42. Futterman S, Andrews JS. The composition of liver vitamin A ester and the synthesis of vitamin A ester by liver microsomes. J Biol Chem 1964;239:4077–4080.
43. Schäffer MW, Roy SS, Mukherjee S, Nohr D, Wolter M, Biesalski HK, Ong DE, Das SK. Qualitative and quantitative analysis of retinol, retinyl esters, tocopherols and selected carotenoids out of various internal organs form different species by HPLC. Anal Methods 2010;2:1320–1332.
44. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedkalka M, Mancina RM, Burza MA, Indiveri C, Ferro Y, Montalbini T, Maglio C, Dongiovanni F, Fargion S, Rametta R, Pujia A, Andersson L, Ghosal S, Levin M, Wiklund O, Iacovino M, Borén J, Romero S. PNPLA3 has retinyl-palmitate lipase activity in human hepaticstellate cells. Hum Mol Genet 2014;23:4077–4085.
45. Aragonés G, Auguet T, Armengol S, Berlanga A, Guij-Jurado E, Aguilar C, Martínez S, Sabench F, Porras RA, Ruiz MD, Hernández M, Sirvent JJ, Del Castillo D, Richart C. PNPLA3 expression is related to liver steatosis in morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci 2016;17:630.
46. Saeed A, Dullaart RPF, Schreuder TCMA, Blokzijl H, Faber KN. Disturbed vitamin A metabolism in non-alcoholic fatty liver disease (NAFLD). Nutrients 2018;10:29.
47. Xu C, Chakravarty K, Kong X, Tuy TT, Arine IJ, Bone F, Massillon D. Several transcription factors are recruited to the glucose-6-phosphatase gene promoter in response to palmitate in rat hepatocytes and H4IIE cells. J Nutr 2007;137:554–559.
48. Zhao N, Li X, Feng Y, Han J, Feng Z, Li X, Wen Y. The nuclear orphan receptor Nur77 alleviates palmitate-induced fat accumulation by down-regulating G0S2 in HepG2 cells. Sci Rep 2018;8:4809.
49. Piccolis M, Bond LM, Kampmann M, Pulimeni P, Chitraju C, Jayson CBK, Fjellat LA, Lai ZW, Gabriel KR, Elliott SD, Paulo JA, Harper JW, Weissman JS, Walther TC, Farese RV. Probing the global cellular responses to lipotoxicity caused by saturated fatty acids. Mol Cell 2019;74:32–44.e8.
50. Dubuquoy C, Robichon C, Lasnier F, Langlois C, Dugail I, Foufelle F, Girard J, Burnol A-F, Postic C, Moldes M. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol 2011;55:145–153.

51. Yang D, Vuckovic MG, Smullin CP, Kim M, Pui–See Lo C, Devericks E, Yoo HS, Tintcheva M, Deng Y, Napoli JI. Modest decreases in endogenous all-trans-retinoic acid produced by a mouse Rdh10Heterozygote provoke major abnormalities in adipogenesis and lipid metabolism. Diabetes 2018;67:662–673.

52. Bartuzi P, Wijshake T, Dekker DC, Fedoseienko A, Kloosterhuis NJ, Youssef SA, Li H, Shiri–Sverdlov R, Kuivenhoven J-A, de Bruin A, Burstein E, Hofker MH, van de Sluis B. A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta 2014;1842:2257–2265.

53. Bartuzi P, Billadeau DD, Favier R, Rong S, Dekker D, Fedoseienko A, Fieten H, Wijers M, Grangl G, Mcgaughan J, Horton JD, Burstein E, Hofker MH, van de Sluis B. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nat Commun 2016;7:10961.

54. Shajari S, Saeed A, Smith-Cortinez NF, Heegsma J, Gruben R, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DPY, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology 2013;57:566–576.

55. Aparicio-Vergara M, Hommelberg PPH, Schreurs M, Gruben R, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DPY, Hofker MH. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc 2008;2008, pdb.prot4986.

56. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 2013;8:1149–1154.

57. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y-C, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.

58. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911–917.

59. Croce AC, De Simone U, Varetti M, Ferrigno A, Boncompagni E, Freitas I, Bottiroli G. Liver autofluorescence properties in animal model under altered nutritional conditions. Photochem Photobiol Sci 2008;7:1046–1053.

Acknowledgments
The authors want to acknowledge Tim Van Zutphen and Dicky Struik for providing samples of ob/ob mice.

CRediT Authorship Contributions
Ali Saeed (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Funding acquisition: Lead; Visualization: Lead; Writing – review & editing: Lead); Klaas Nico Faber (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – review & editing: Lead).

Conflicts of Interest
The authors disclose no conflicts.

Funding
This work was supported by the Dutch Digestive Disease Foundation, grant numbers MWO 03–38 (to Klaas Nico Faber) and MWO 08–70 (to Klaas Nico Faber).

Received October 3, 2019. Accepted July 16, 2020.

Correspondence
Address correspondence to: Klaas Nico Faber, PhD, Department Hepatology & Gastroenterology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. e-mail:k.n.faber@umcg.nl; fax: +31(0)503619306; or Ali Saeed, PhD, Department Hepatology & Gastroenterology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. e-mail:a.saeed@umcg.nl; fax: +31(0)503619306.
**Supplementary Table 1. Pearson Correlation Analysis of Vitamin A With Various Parameters of NAFLD in Mice Fed High-Fat, High-Cholesterol Diet**

|                        | Retinol | Retinyl palmitate | Plasma retinol | Total cholesterol |
|------------------------|---------|-------------------|----------------|------------------|
| **r**                  |         |                   |                |                  |
| Retinol                | 1.000   |                   |                |                  |
| Retinyl palmitate      | -.5090<sup>a</sup> | .0094<sup>a</sup> | 1.000          |                  |
| Plasma retinol         | -.8336<sup>a</sup> | .0001<sup>a</sup> | .3138<sup>a</sup> | .155<sup>a</sup> | 1.000 |
| Total cholesterol      | -.6705<sup>a</sup> | .0002<sup>a</sup> | .4537<sup>a</sup> | .0227<sup>a</sup> | .4132<sup>a</sup> | .0447<sup>a</sup> | 1.000 |
| Free cholesterol       | -.6163<sup>a</sup> | .0023<sup>a</sup> | .2172<sup>a</sup> | .3316<sup>a</sup> | .3996<sup>a</sup> | .0654<sup>a</sup> | .8713<sup>a</sup> | <.0001<sup>a</sup> |
| Triglycerides          | -.7264<sup>a</sup> | <.0001<sup>a</sup> | .4399<sup>a</sup> | .0357<sup>a</sup> | .3746<sup>a</sup> | .0858<sup>a</sup> | .8338<sup>a</sup> | <.0001<sup>a</sup> |
| Plasma total cholesterol| -.8558<sup>a</sup> | <.0001<sup>a</sup> | .3956<sup>a</sup> | .0557<sup>a</sup> | .7992<sup>a</sup> | <.0001<sup>a</sup> | .7002<sup>a</sup> | <.0001<sup>a</sup> |
| Plasma free cholesterol| -.6987<sup>a</sup> | .0001<sup>a</sup> | .3970<sup>a</sup> | .0547<sup>a</sup> | .7933<sup>a</sup> | <.0001<sup>a</sup> | .6201<sup>a</sup> | .0007<sup>a</sup> |
| Plasma insulin         | -.4819<sup>a</sup> | .0199<sup>a</sup> | .1850<sup>a</sup> | .3981<sup>a</sup> | .3288<sup>a</sup> | .1352<sup>a</sup> | .4454<sup>a</sup> | .0257<sup>a</sup> |
| Ldlr                   | -.3034<sup>a</sup> | .1404<sup>a</sup> | -.0385<sup>a</sup> | .8552<sup>a</sup> | .3247<sup>a</sup> | .1216<sup>a</sup> | .0712<sup>a</sup> | .724<sup>a</sup> |
| Srb1                   | -.4420<sup>a</sup> | .0269<sup>a</sup> | .3330<sup>a</sup> | .1038<sup>a</sup> | .2512<sup>a</sup> | .2364<sup>a</sup> | .6968<sup>a</sup> | <.0001<sup>a</sup> |
| Cd36                   | -.7852<sup>a</sup> | <.0001<sup>a</sup> | .4761<sup>a</sup> | .0161<sup>a</sup> | .8182<sup>a</sup> | <.0001<sup>a</sup> | .5167<sup>a</sup> | .0058<sup>a</sup> |
| Scd1                   | -.8337<sup>a</sup> | <.0001<sup>a</sup> | .4571<sup>a</sup> | .0216<sup>a</sup> | .7339<sup>a</sup> | <.0001<sup>a</sup> | .6488<sup>a</sup> | .0003<sup>a</sup> |
| Fasn                   | -.6557<sup>a</sup> | .0044<sup>a</sup> | .2310<sup>a</sup> | .2666<sup>a</sup> | .5699<sup>a</sup> | .0036<sup>a</sup> | .3909<sup>a</sup> | .0438<sup>a</sup> |
| Acc1                   | -.6317<sup>a</sup> | .0007<sup>a</sup> | .2304<sup>a</sup> | .2679<sup>a</sup> | .5549<sup>a</sup> | .0049<sup>a</sup> | .4235<sup>a</sup> | .0277<sup>a</sup> |
| Tnfa                   | -.6956<sup>a</sup> | .0001<sup>a</sup> | .2370<sup>a</sup> | .2541<sup>a</sup> | .8304<sup>a</sup> | .0001<sup>a</sup> | .5063<sup>a</sup> | .0071<sup>a</sup> |
| Nos2                   | -.5468<sup>a</sup> | .0057<sup>a</sup> | .3073<sup>a</sup> | .1441<sup>a</sup> | .6059<sup>a</sup> | .0022<sup>a</sup> | .3951<sup>a</sup> | .0457<sup>a</sup> |
| Ccl2                   | -.6086<sup>a</sup> | .0012<sup>a</sup> | .2781<sup>a</sup> | .1784<sup>a</sup> | .7633<sup>a</sup> | <.0001<sup>a</sup> | .4329<sup>a</sup> | .0241<sup>a</sup> |
| Itlb                   | -.6533<sup>a</sup> | .0004<sup>a</sup> | .4088<sup>a</sup> | .0425<sup>a</sup> | .3854<sup>a</sup> | .0629<sup>a</sup> | .6062<sup>a</sup> | .0008<sup>a</sup> |
| Il6                    | -.3023<sup>a</sup> | .1511<sup>a</sup> | .3158<sup>a</sup> | .1327<sup>a</sup> | .0613<sup>a</sup> | .7863<sup>a</sup> | .4628<sup>a</sup> | .0198<sup>a</sup> |
| Co1a1                  | -.6398<sup>a</sup> | .0006<sup>a</sup> | .1263<sup>a</sup> | .5473<sup>a</sup> | .7626<sup>a</sup> | <.0001<sup>a</sup> | .4320<sup>a</sup> | .0244<sup>a</sup> |
| Acta2                  | -.6355<sup>a</sup> | .0006<sup>a</sup> | .1773<sup>a</sup> | .3965<sup>a</sup> | .6210<sup>a</sup> | .0012<sup>a</sup> | .5299<sup>a</sup> | .0045<sup>a</sup> |
| Tgfb                   | -.7158<sup>a</sup> | <.0001<sup>a</sup> | .2572<sup>a</sup> | .2145<sup>a</sup> | .7649<sup>a</sup> | <.0001<sup>a</sup> | .6454<sup>a</sup> | .0003<sup>a</sup> |
| Timp1                  | -.5585<sup>a</sup> | .0037<sup>a</sup> | .0657<sup>a</sup> | .7552<sup>a</sup> | .7044<sup>a</sup> | .0001<sup>a</sup> | .3541<sup>a</sup> | .07<sup>a</sup> |

Pearson correlation analysis of hepatic vitamin A (retinol, retinyl palmitate) with circulatory vitamin A (plasma retinol) with various parameters of diet-induced NAFLD progression. A correlation was also calculated between tissue and circulatory vitamin A with hepatic gene expression of markers for the progression of NAFLD. D P ≤ .05 considered significant. NAFLD, nonalcoholic fatty liver disease.

<sup>a</sup>Significant inverse correlation.

<sup>b</sup>Positive correlation.
| Gene/ID | TaqMan primers and probe |
|---------|--------------------------|
| 36B4 | Fwd: 5’-GCTTATTGGGAGACGAC-3'  
Rev: 5’-CAGGTCCTCTATGGCAGA-3'  
Probe: 5’-TCTCAATGCTGACTCCAGG-3' |
| Acaca/Acc1 | Fwd: 5’-CACATTGGATGATGAGGCTC-3’  
Rev: 5’-CGGACAGACAGGACTGGTG-3’  
Probe: 5’-TTGAGACCTTCATTGCTCGAGC-3’ |
| Act2/α-Sma | Fwd: 5’-GCACGGGAGCGACTCTCCT-3’  
Rev: 5’-GCAACGGACCCAGATGGAG-3’  
Probe: 5’-CAACGGTCAGCCACCTCCTTGCTG-3’ |
| Cd36 | Fwd: 5’-GAGGACGAGCAGAAGACTGTT-3’  
Rev: 5’-GGTTCCTTCTTCAAGGACAA ACTTT-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Ccl2 | Fwd: 5’-GTGCTGCAAGGACAGCATCT-3’  
Rev: 5’-CAGATACACCCCTTGGACAC-3’  
Probe: 5’-TCTCTGCTTGTCCTCCCGGAAAC-3’ |
| Col1a1 | Fwd: 5’-GTGCGGAGCGACGACCTCCT-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Cpt1a | Fwd: 5’-GTGCGGAGCGACGACCTCCT-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Dgat1 | Fwd: 5’-GTGCGGAGCGACGACCTCCT-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Dgat2 | Fwd: 5’-GTGCGGAGCGACGACCTCCT-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Fasn | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Fgf21 | Fwd: 5’-GTGCGGAGCGACGACCTCCT-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Hsd17b13 | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| Lipe/HSL | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| IL-1β | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| IL-6 | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
| iNos/Nos2 | Fwd: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Rev: 5’-GGAGAGGAGAGTCACCTGTG-3’  
Probe: 5’-AGAATGCTTCCAACACACGAGGAC-3’ |
### Supplementary Table 2. Continued

| Gene/ID | TaqMan primers and probe |
|---------|--------------------------|
| *Ldlr*  | Fwd: 5'-GCACTGACTGCTGACAGGTGT-3'  |
|         | Rev: 5'-GGGAGACCCACCATGTTG-3'     |
|         | Probe: 5'-CAGCTCCGTTGACGCTCCGACC-3' |
| *Lpl*   | Fwd: 5'-CTCGAGAGTCTGTTGAGACAGAT-3' |
|         | Rev: 5'-CCCTCACCTCAGTTGAGACTGTTG-3' |
|         | Probe: 5'-ACTGAGATATGGAGGATGCAGT-3' |
| *Lrat*  | Fwd: 5'-AGGTCAGAGCCAAGAGAAGCA-3'  |
|         | Rev: 5'-CCAGAAAAGTGAATCTTGACTTTG-3' |
|         | Probe: 5'-CCTGAAGACTCGCTCTCAGAT-3' |
| *LRAT*  | Fwd: 5'-TGCGAGCACTTCGTGACCTA-3'   |
|         | Rev: 5'-TTATCTTCACAGTCTCACAAAACTTG-3' |
|         | Probe: 5'-TGCGAGCACTTCGTGACCTA-3' |
| *Pck1*  | Fwd: 5'-GTGTCATCCGCAAGCTGAAG-3'   |
|         | Rev: 5'-CTTTCGATCCTGGCAACAATACT-3' |
|         | Probe: 5'-CAACTGTTGGCTGGCTCTCACCC-3' |
| *Ppargc1a* | Fwd: 5'-GACCCCAGAGTCACCAAATGA-3' |
|         | Rev: 5'-GGCCTGCAGTTCCAGAGAGT-3'   |
|         | Probe: 5'-CCCCATTTGAGAACAAGACTATTGAGCGAACC-3' |
| *Pnpla2/Atgl* | Fwd: 5'-AGCATCTGCCAGTATCTGGTGAT-3' |
|         | Rev: 5'-CACCTGCTCAGACAGTCTGGAA-3'  |
|         | Probe: 5'-ATGGTCACCCAATTTCCTCTTGGCCC-3' |
| *Pnpla3* | Fwd: 5'-CTGTACCCTGCCTGTGGAATCT-3' |
|         | Rev: 5'-AGGACATCGTCGGGCATATCT-3'  |
|         | Probe: 5'-CCATGTCACCAGTCTCTGGACAATCGC-3' |
| *RAR-β* | Assay on demand, Mm01319677_m1 (ThermoFisher) |
| *Raldh* | Assay on demand, Mm0067317_m1 (ThermoFisher) |
| *Raldh4* | Assay on demand, Mm00474049_m1 (ThermoFisher) |
| *Rbp4*  | Fwd: 5'-GGTGGGCACTTTCACAGACA-3'   |
|         | Rev: 5'-GATCCAGTGGTCATCGTTTCCT-3'  |
|         | Probe: 5'-CCCCAGTACTTCATCTTGAGAGGG-3' |
| *Scd1*  | Fwd: 5'-ATGCTCCAAGAGATCTCCAGTTT-3' |
|         | Rev: 5'-GGGCTACCATGCTCGCTTGTG-3'   |
|         | Probe: 5'-CGCTGCCCTTACATCGCTCCGACC-3' |
| *TGF-β1* | Fwd: 5'-GGGCTACCATGCTCGCTTGTG-3' |
|         | Rev: 5'-GGGCTACCATGCTCGCTTGTG-3'   |
|         | Probe: 5'-CGCTGCCCTTACATCGCTCCGACC-3' |
| *Timp1* | Fwd: 5'-TCTGAGCAGCTGCTCGAGCAA-3'  |
|         | Rev: 5'-AACAGGAAACACTGCTGACACC-3' |
|         | Probe: 5'-CCACGACCGACTATAGGTCTTTGAGAAACG-3' |
| *TNF-α* | Fwd: 5'-GCAACCACCAAGCAGTTG-3'    |
|         | Rev: 5'-ACCAGCTCAGACAGTTGACA-3'   |
|         | Probe: 5'-CAGAGGCGCCGATCCCTCC-3'  |
| *Ucp2*  | Fwd: 5'-CAACCACCAAGCAGTTG-3'     |
|         | Rev: 5'-ACCAGCTCAGACAGTTGACA-3'   |
|         | Probe: 5'-CAGAGGCGCCGATCCCTCC-3'  |